open access

Vol 67, No 6 (2016)
Original papers
Published online: 2016-12-30
Submitted: 2016-05-10
Accepted: 2016-07-29
Get Citation

Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly

Przemysław Witek, Sławomir Mucha, Marek Ruchała
DOI: 10.5603/EP.2016.0066
·
Endokrynologia Polska 2016;67(6):572-579.

open access

Vol 67, No 6 (2016)
Original papers
Published online: 2016-12-30
Submitted: 2016-05-10
Accepted: 2016-07-29

Abstract

Introduction: Despite the known importance of somatostatin analogues (SSAs) in the treatment of acromegaly, patient satisfaction leading to preferences for specific SSAs have received little attention so far.

Material and methods: This open, prospective, observational, multicentre patient-reported outcome study included adult patients with acromegaly, who switched from another SSA to lanreotide Autogel (new and previous devices) at least two months prior to enrolment. The observation period was around 12 months. The primary outcome assessed was overall treatment satisfaction, measured using the five-point Likert scale. The secondary outcomes were: 1) treatment effectiveness, in terms of symptom control; 2) technical problems related to treatment administration, measured by the Visual Analog Scale (VAS); and 3) ease and safety of lanreotide Autogel delivery (new device vs. previous device).

Results: Of the 102 patients who completed the study, 97 (95.1%) were “completely or rather satisfied” with lanreotide Autogel therapy, four (3.9%) were “neither satisfied nor dissatisfied”, and one (1%) was “rather dissatisfied”. Symptom control was reported as “excellent” or “good” by 88–89% of patients throughout the study. Patients reported fewer technical problems related to administration of lanreotide Autogel (final mean VAS: 5.3) compared to previous SSAs (mean VAS: 37.6). Of the 31 patients treated with lanreotide Autogel using the previous device followed by the new device, 64.5% reported the new device as improved.

Conclusions: Lanreotide Autogel therapy resulted in greater patient satisfaction with overall acromegaly management, when compared to previous SSAs. The new lanreotide Autogel device was found to be easier to use than the previous one. (Endokrynol Pol 2016; 67 (6): 572–579)

Abstract

Introduction: Despite the known importance of somatostatin analogues (SSAs) in the treatment of acromegaly, patient satisfaction leading to preferences for specific SSAs have received little attention so far.

Material and methods: This open, prospective, observational, multicentre patient-reported outcome study included adult patients with acromegaly, who switched from another SSA to lanreotide Autogel (new and previous devices) at least two months prior to enrolment. The observation period was around 12 months. The primary outcome assessed was overall treatment satisfaction, measured using the five-point Likert scale. The secondary outcomes were: 1) treatment effectiveness, in terms of symptom control; 2) technical problems related to treatment administration, measured by the Visual Analog Scale (VAS); and 3) ease and safety of lanreotide Autogel delivery (new device vs. previous device).

Results: Of the 102 patients who completed the study, 97 (95.1%) were “completely or rather satisfied” with lanreotide Autogel therapy, four (3.9%) were “neither satisfied nor dissatisfied”, and one (1%) was “rather dissatisfied”. Symptom control was reported as “excellent” or “good” by 88–89% of patients throughout the study. Patients reported fewer technical problems related to administration of lanreotide Autogel (final mean VAS: 5.3) compared to previous SSAs (mean VAS: 37.6). Of the 31 patients treated with lanreotide Autogel using the previous device followed by the new device, 64.5% reported the new device as improved.

Conclusions: Lanreotide Autogel therapy resulted in greater patient satisfaction with overall acromegaly management, when compared to previous SSAs. The new lanreotide Autogel device was found to be easier to use than the previous one. (Endokrynol Pol 2016; 67 (6): 572–579)

Get Citation

Keywords

acromegaly; somatostatin analogues; lanreotide; octreotide; patient preferences; observational study

About this article
Title

Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly

Journal

Endokrynologia Polska

Issue

Vol 67, No 6 (2016)

Pages

572-579

Published online

2016-12-30

DOI

10.5603/EP.2016.0066

Bibliographic record

Endokrynologia Polska 2016;67(6):572-579.

Keywords

acromegaly
somatostatin analogues
lanreotide
octreotide
patient preferences
observational study

Authors

Przemysław Witek
Sławomir Mucha
Marek Ruchała

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl